Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

NCT ID: NCT02492165

Last Updated: 2022-03-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 250 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2016-06-30

Brief Summary

The purpose of this study is to describe the immunogenicity and safety of IMOJEV® in adult and pediatric populations in Vietnam and serve a bridging study to compare immunogenicity, reactogenicity, and safety data obtained with IMOJEV® in the Vietnamese population with data from other Asian pediatric populations.

Primary objective:

• To describe the safety profile of a single dose of IMOJEV®.

Secondary objectives:

• To evaluate the immune response to JE 28 days after the administration of a single dose of IMOJEV® in healthy Vietnamese subjects aged from 9 months to 60 years.

Detailed Description

Study participants will be enrolled by age group and will each receive one injection of IMOJEV® on Day 0 given as primary vaccination. They will be assessed for immunogenicity and safety, post-vaccination.

Conditions

Japanese Encephalitis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Age 9 Months through 4 Years Group

Participants age 9 Months through 4 Years old at enrollment

Group Type: EXPERIMENTAL

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

Intervention Type: BIOLOGICAL

0.5 mL, Subcutaneous

Age 5 Years through 11 Years Group

Participants age 5 Years through 11 Years old at enrollment

Group Type: EXPERIMENTAL

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

Intervention Type: BIOLOGICAL

0.5 mL, Subcutaneous

Age 12 Years through 17 Years Group

Participants age 12 Years through 17 Years old at enrollment

Group Type: EXPERIMENTAL

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

Intervention Type: BIOLOGICAL

0.5 mL, Subcutaneous

Age 18 Years through 60 Years Group

Participants age 18 Years through 60 Years old at enrollment

Group Type: EXPERIMENTAL

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

Intervention Type: BIOLOGICAL

0.5 mL, Subcutaneous

Interventions

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

0.5 mL, Subcutaneous

Intervention Type: BIOLOGICAL

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

0.5 mL, Subcutaneous

Intervention Type: BIOLOGICAL

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

0.5 mL, Subcutaneous

Intervention Type: BIOLOGICAL

Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)

0.5 mL, Subcutaneous

Intervention Type: BIOLOGICAL

Other Intervention Names

IMOJEV®; IMOJEV®; IMOJEV®; IMOJEV®

Eligibility Criteria

Inclusion Criteria

• Aged 9 months through 60 years on the day of inclusion.
• For adults: Informed consent form has been signed and dated by the subject. For minors: Informed consent form has been signed and dated by the parent or legally acceptable representative. In addition, in accordance with the Institution Ethics Committee / Institution Review Board requirements and as appropriate for the age of the subject, the subject may be required to sign and date the informed consent form if aged 12 to 17 years or assent form if aged 8 to 11 years.
• Subject and parent(s)/legally acceptable representative(s) are able to attend all scheduled visits and comply with all study procedures.

Exclusion Criteria

• Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche, or post-menopausal for at least 1 year, or surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination).
• Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or a medical procedure.
• Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine in the 4 weeks following the study vaccination, except for inactivated influenza vaccination, which may be received at least 2 weeks before the study vaccine
• Previous vaccination against flavivirus disease, including Japanese Encephalitis (JE), dengue, and yellow fever.
• Receipt of immune globulins, blood, or blood-derived products in the past 3 months that might interfere with the assessment of the immune response.
• Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy (for more than 2 consecutive weeks within the 4 weeks preceding vaccination).
• History of flavivirus infection (confirmed either clinically, serologically, or virologically).
• History of central nervous system disorder or disease, including seizures.
• Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the study or to a vaccine containing any of the same substances.
• Known thrombocytopenia, contraindicating vaccination.
• Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating vaccination.
• Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
• Current alcohol abuse or drug addiction.
• Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion.
• Febrile illness (temperature ≥ 38.0°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment. A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
• Receipt of any chronic anti-viral in the 2 months preceding the study vaccination or planned receipt of any anti-viral in the 4 weeks following the study vaccination. Short-term antiviral drugs for flu or herpes can be administered provided there is a wash-out period of 1 week before the administration of the vaccine.
• Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.

• Minimum Eligible Age: 9 Months
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Hygiene and Epidemiology, Vietnam

OTHER

Sponsor Role: collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Sanofi Pasteur SA

Locations

Preventive Medicine Centre of Hoa Binh Province

Hòa Bình, , Vietnam

Countries

Vietnam

References

Vu TD, Nguyen QD, Tran HTA, Bosch-Castells V, Zocchetti C, Houillon G. Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study. Int J Infect Dis. 2018 Jan;66:137-142. doi: 10.1016/j.ijid.2017.10.010. Epub 2017 Nov 27.

Reference Type: DERIVED

PMID: 29081368 (View on PubMed)

Related Links

http://www.sanofipasteur.com

Related Info

Other Identifiers

U1111-1143-8142

Identifier Type: OTHER

Identifier Source: secondary_id

JEC13

Identifier Type: -

Identifier Source: org_study_id

NCT02821221

Identifier Type: -

Identifier Source: nct_alias